SLC43A1 and cancer: There is little to no exploration of oxaliplatin being used as a therapeutic agent for AML, liver (36), prostate (37), and testicular (38) cancers, and perhaps the upregulation of LAT3 observed in these tumor tissues could facilitate an initial response.